We build companies that change patient outcomes.
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients.
Cell Design Labs
Cell Design Labs is a private biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power, precision, safety and durability.
Kite, a Gilead company, is a leader in developing and commercializing autologous chimeric antigen receptor T-cell (CAR T) and T cell receptor (TCR) therapies for the treatment of cancer. In 2017, Kite received approval for Yescarta™, the first FDA approved CAR T therapy for the treatment of adult patients with certain types of large B-cell lymphoma. Kite was acquired by Gilead in 2017 for $11.9 billion.
Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.
Neogene Therapeutics, Inc., now part of AstraZenca, is pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for patients with solid tumors by targeting cancer-specific neoantigens. Neogene was acquired by AstraZeneca in 2023.
Symbiotic Capital is a global healthcare credit firm that brings together decades of expertise across science, finance, and entrepreneurship. Symbiotic structures and originates credit solutions to compelling healthcare companies to support scientific innovation across biotechnology, medical devices, diagnostics, tools, synthetic biology, consumer health, and other healthcare subsectors.
